Ardelyx (ARDX) Total Current Liabilities (2013 - 2026)
Ardelyx (ARDX) posted Total Current Liabilities of $109.6 million for Q1 2026, up 23.66% on a QoQ basis from $88.6 million in Q4 2025, and up 44.47% year-over-year from $75.8 million in Q1 2025.
Ardelyx (ARDX) Total Current Liabilities (2013 - 2026) Analysis & Trends
Ardelyx's Total Current Liabilities history runs 14 years deep, the most recent figure standing at $109.6 million for Q1 2026.
- Quarterly Total Current Liabilities rose 44.47% year-over-year to $109.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $109.6 million (up 44.47% YoY) and the FY2025 annual result came in at $88.6 million, up 13.84% from the prior year.
- Total Current Liabilities was $109.6 million for Q1 2026 at Ardelyx, up from $88.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $109.6 million in Q1 2026 and bottomed at $43.5 million in Q3 2023.
- A 5-year average of $67.0 million and a median of $63.1 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities decreased 24.45% — and 2024, when it surged 61.96%.
- Ardelyx's Total Current Liabilities stood at $65.6 million in 2022, then dropped by 23.18% to $50.4 million in 2023, then surged by 54.45% to $77.8 million in 2024, then increased by 13.84% to $88.6 million in 2025, then gained by 23.66% to $109.6 million in 2026.
- Business Quant data shows ARDX's Total Current Liabilities at $109.6 million in Q1 2026, $88.6 million in Q4 2025, and $83.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Ardelyx | 1.26 Bn | 1.02 Bn | 89.66 Mn | 109.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109.57 Mn |
| Dec 31, 2025 | 88.61 Mn |
| Sep 30, 2025 | 83.39 Mn |
| Jun 30, 2025 | 81.72 Mn |
| Mar 31, 2025 | 75.84 Mn |
| Dec 31, 2024 | 77.83 Mn |
| Sep 30, 2024 | 70.50 Mn |
| Jun 30, 2024 | 62.44 Mn |
| Mar 31, 2024 | 56.90 Mn |
| Dec 31, 2023 | 50.39 Mn |
| Sep 30, 2023 | 43.53 Mn |
| Jun 30, 2023 | 61.69 Mn |
| Mar 31, 2023 | 63.06 Mn |
| Dec 31, 2022 | 65.60 Mn |
| Sep 30, 2022 | 51.95 Mn |
| Jun 30, 2022 | 48.70 Mn |
| Mar 31, 2022 | 47.84 Mn |
| Dec 31, 2021 | 52.82 Mn |
| Sep 30, 2021 | 68.77 Mn |
| Jun 30, 2021 | 57.79 Mn |